Related trials

IMPROVE-IT, 2014 - ezetimibe vs control

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

SEARCH, 2010 - simvastatin high dose vs simvastatin

SHARP, 2010 - ezetimibe+simvastatin vs placebo

ARBITER-HALTS 6, 2010 - ezetimibe vs niacin

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

ARBITER 2, 2009 - niacin vs placebo (on top statin)

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

JUPITER, 2008 - rosuvastatin vs placebo

Tuttle, 2008 - low fat diet vs mediterranean-style diet

GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo

SANDS, 2008 - aggressive treatment vs standard teatment

SAGE, 2007 - atorvastatin high dose vs pravastatin

Krum, 2007 - rosuvastatin vs placebo

METEOR, 2007 - rosuvastatin vs placebo

CORONA, 2007 - rosuvastatin vs placebo

SPARCL, 2006 - atorvastatin vs placebo

ASPEN, 2006 - atorvastatin vs placebo

MEGA, 2006 - pravastatin vs control

WHI low fat, 2005 - diet vs usual diet

Hong, 2005 - simvastatin vs control

IDEAL, 2005 - atorvastatin high dose vs simvastatin

Vascular basis, 2005 - atorvastatin high dose vs lovastatin

ARBITER-HALTS 6 study, 2010	TRC10015
	download pdf: ezetimibe | cholesterol lowering intervention for cardiovascular prevention

Treatments

Studied treatment	addition of ezetimibe (10 mg/daily) to statin therapy
Control treatment	extended-release niacin 2000 mg/daily

Patients

Patients

patients at high risk for vascular disease but with LDL-cholesterol levels <100 mg/dL and moderately low HDL-cholesterol levels (<50 mg/dL)

Method and design

Randomized effectives	NA / NA (studied vs. control)
Design	Parallel groups
Blinding	open
Follow-up duration	14 months
Premature discontinuation	Premature discontinuation for efficacy
Hypothesis	Superiority
Primary endpoint	carotid IMT
Remarks	stopped early on the basis of a prespecified interim analysis showing that niacin was superior to ezetimibe on the end point of change in the carotid IMT

Remarks / Comments

The trial was stopped early on the basis of a prespecified interim analysis showing that niacin was superior to ezetimibe on the end point of change in the carotid IMT

Results

No results available for this trial - no clinical endpoint reported

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for high risk patients with or without LDL cholesterol elevation

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

Reference(s)

TrialResults-center ID	TRC10015
Trials register #	NA